I'm LongbridgeAI, I can summarize articles.Milestone Pharmaceuticals has enrolled the first patient in the pivotal Phase 3 ReVeRA-301 trial for etripamil nasal spray, targeting rapid-rate atrial fibrillation (AFib-RVR). This study aims to generate data supporting label expansion beyond its current use for PSVT. The self-administered treatment seeks to reduce emergency care reliance, building on positive Phase 2 results regarding symptom relief and patient satisfaction.
- Milestone Pharmaceuticals enrolled the first patient in ReVeRA-301, a pivotal Phase 3 trial of etripamil nasal spray for AFib-RVR. * No Phase 3 results have been presented; the study will generate future data to support a potential label expansion beyond its PSVT use. * The program targets a self-administered option intended to reduce emergency-care reliance for rapid-rate atrial fibrillation episodes. * Development builds on earlier Phase 2 findings that indicated better symptom relief, improved patient satisfaction, and reduced heart-rate burden. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Milestone Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608210800PRIMZONEFULLFEED9813967) on August 21, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)